Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.
Market Dynamics
Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.
Key features of the study:
- This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics
- The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts
- Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
- Global Rivaroxaban Market, By Strength:
- Global Rivaroxaban Market, By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- Global Rivaroxaban Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Rivaroxaban Market, By Region:
- North America
- By Strength:
- By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Strength:
- By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Strength:
- By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By country:
- Germany
- U.K.
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Strength:
- By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- By Strength:
- By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Strength:
- By Application:
- Deep Vein Thrombosis Prophylaxis
- Pulmonary Embolism
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By country:
- North Africa
- Central Africa
- South Africa
- Company Profiles
- Janssen Pharmaceuticals Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- Bayer AG
“*” marked represents similar segmentation in other categories in the respective section.
